Results following treatment to doses of 92.4 or 102.9 Gy on a phase I dose escalation study for non-small cell lung cancer
| Autor: | Samir Narayan, Randall K. Ten Haken, M.K. Martel, James A. Hayman, Molly A Sullivan, G.T. Henning |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Male
Pulmonary and Respiratory Medicine Cancer Research Lung Neoplasms Pulmonary toxicity medicine.medical_treatment Carcinoma Non-Small-Cell Lung medicine Esophagitis Humans Lung volumes Radiation Injuries Radiometry Lung cancer Radiation treatment planning Survival analysis Aged business.industry Dose-Response Relationship Radiation Middle Aged medicine.disease Survival Analysis Respiratory Function Tests Radiation therapy Treatment Outcome Oncology Toxicity Disease Progression Female business Nuclear medicine |
| Zdroj: | Lung Cancer. 44:79-88 |
| ISSN: | 0169-5002 |
| Popis: | Background and Purpose: The University of Michigan lung dose escalation study has increased the dose of external beam radiation for non-small cell lung cancer based on the volume of normal lung irradiated. The results of patients treated to either 92.4 or 102.9 Gy are reported. Materials and Methods: Seventeen patients have completed treatment to 92.4 or 102.9 Gy and have been followed for at least 6 months. The treatment planning goal was to minimize the effective volume (Veff) of total lung irradiated as computed using the Kutcher–Burman DVH reduction scheme. Dose was escalated independently within each of five Veff bins. Toxicity, freedom from local progression (FFLP), overall survival (OS) and cause specific survival (CSS) are reported. Results: Thirteen patients were Stage I, one was Stage II and three were Stage III. Veff ranged from 0.06 to 0.21. The median pretreatment FEV1 was 1.24L or 44% of predicted. Median follow-up for survivors was 37.9 months. No patient had significant pulmonary toxicity. One patient each had grades 2 and 3 esophagitis. Median percent change in FEV1 was −11%. Two- and three-year actuarial FFLP and OS rates for the entire group were 68 and 58% and 51 and 26%, respectively. For Stage I patients, the 2 and 3 year FFLP, OS and CSS rates were 82 and 68%, 54 and 33%, 76 and 48% respectively. Conclusions: These results suggest that doses of radiation of 92.4 and 102.9 Gy can be delivered safely to limited lung volumes with minimal toxicity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect